Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday? Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025.
VSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024 VSTM stock results show that Verastem beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with!
7 F-Rated Stocks to Avoid at All Costs in June The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June.
Is the Stock Market Open on Memorial Day 2024? Investors wondering if the stock market is open on Memorial Day in 2024 need look no further as we have the answer to that question!
7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split Nvidia is a hot topic among traders on Friday after the company provided investors with details of an NVDA stock split next month.
NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial Netlist stock is down on Friday with heavy NLST trading after a court ruled in favor of the company in a patent battle with Micron.
Why Is Verastem (VSTM) Stock Down 62% Today? Verastem stock is down on Friday with heavy trading of VSTM shares alongside its latest pancreatic cancer clinical trial safety data.
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant ovarian cancer is underway.
